Background
==========

Diabetes is a leading cause of morbidity and mortality in the United States \[[@B1]\] and is a key independent risk factor for a number of microvascular and macrovascular diseases. According to the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) Consensus Statement, type 2 diabetes is characterized by progressive loss of beta cell function and a corresponding need for progressive and early addition of glucose lowering strategies \[[@B2]\]. Achieving and maintaining glycemic control as a primary treatment goal for the management of type 2 diabetes is challenging.

Several studies have examined glucose lowering treatment patterns for type 2 diabetes, showing suboptimal use and poor adherence/persistency with current therapies \[[@B3]-[@B5]\]. Failure to continue their glucose lowering medications may be associated with adverse outcomes including both clinical as well as economics consequences. The Third National Health and Nutrition Examination Survey found that many patients with type 2 diabetes fail to achieve optimal glycemic control and are at increased risk of developing complications \[[@B6]\]. A review article by Cramer reported that poor adherence to glucose lowering medications may lead to suboptimal glycemic control and also be associated with increased healthcare resource utilization and costs (e.g. due to hospitalizations, temporary or permanent disability because of diabetes related complications) \[[@B7]\]. Stuart et al. reported a positive relationship between persistency to glucose lowering medication and decreased healthcare costs and lower hospitalization rates \[[@B8]\].

Inadequate glycemic control may signal the need for assessment and treatment modification. In order to improve patient outcomes, it is essential to understand the medication use behavior of comparatively newer therapies such as exenatide BID (exenatide), a glucagon like peptide 1 (GLP-1) receptor agonist and insulin glargine (glargine) for the treatment of type 2 diabetes. Although, the clinical efficacy of both exenatide and glargine are well established, there is little information available on the 'real-world' economic and medication utilization patterns of these therapies. Hence, drug utilization studies using administrative pharmacy claims data can provide useful insights into the prescribing patterns and patient medication-taking behavior for exenatide and glargine in usual-care settings.

The goal of this retrospective observational study was to understand more clearly the progression of treatment patterns for patients initiating exenatide or glargine using an evaluation of the rates, timing and likelihood of treatment modification. This information may be particularly useful for health plans and providers planning interventions aimed at improving patient glycemic control and other health outcomes.

Methods
=======

Study design
------------

A retrospective, observational study was conducted, using a large managed care claims database that comprised of patients with type 2 diabetes initiating exenatide or glargine treatment. Data were derived from the MarketScan® Commercial Claims and Encounters (Commercial) Database and the Medicare Supplemental and Coordination of Benefits (COB) (Medicare) Database.

Patient selection
-----------------

Patients aged 18 years and older with at least one prescription claim for exenatide or glargine from October 1, 2006 through March 31, 2008 were selected and screened for continuous eligibility for the 12 months pre- and 18 months post-index period. The index date was defined as the date of the first exenatide or glargine prescription in the above time window.

To ensure the inclusion of only patients with type 2 diabetes, patients were excluded if they had a medical claim with a diagnosis code for gestational diabetes or type 1 diabetes. Patients with diagnosis code for chronic kidney disease, Cushing syndrome, acromegaly, a gastric bypass or banding procedure or occurrence of ≥2 prescription claims for a systemically administered glucocorticoid were also excluded. Patients who lacked a pharmacy benefit or transitioned from the Commercial to Medicare database during the pre- and post-index were also excluded in order to appropriately track their medication use patterns. Patients with any of the following prescriptions in the pre-index period were excluded: pramlintide, sitagliptin, exenatide or insulin (including glargine). Study diagnosis, procedure, and drug codes are available from the authors.

Outcomes measurement
--------------------

### Variables

Demographic variables included gender, age, geographic region, and health plan type. Clinical variables measured included the presence of diabetes related microvascular complications (diabetic retinopathy and macular edema; diabetic neuropathy; amputation and ulceration; renal disease) and macrovascular complications (myocardial infarction; ischemic heart disease; congestive heart failure; peripheral vascular disease; cerebrovascular disease) and presence of common comorbidities (hypertension; dyslipidemia; depression; obesity; hypoglycemia). The Deyo Charlson Comorbidity index (CCI) \[[@B9]\] score was calculated to measure the severity of comorbid conditions. The study also captured the provider specialty, pre-index use of medications, average number of prescriptions and average number of drug classes administered by patients.

### Treatment modification

**Treatment modification** in the matched cohorts was defined as the first event of change in the index medication in the 18 months post-index period and was classified further into 3 types: intensification, switching or discontinuation of the index medication.

**Discontinuation** was defined as a 90-day gap following the end of the days' supply of the previous prescription claim for an index medication, ***without*** any other prescription for a non-index glucose-lowering therapy in that 90-day gap. **Switching** was defined as a prescription claim for a non-index glucose lowering medication without a refill of the index medication in the 90 days following the end of the days' supply of the previous claim for the index prescription, ***with*** at least one refill of the new glucose lowering medication in the 90 days. **Intensification** was defined as the addition of a non-index glucose-lowering medication; continuation of a pre-index medication does not qualify as intensification. Additions were indicated by a non-index glucose-lowering medication prescription with overlap of its days' supply with that of the index medication, followed by refills of the index medication and the added medication in the 90 days following the end of the days' supply specific to each medication. Exenatide intensification was indicated by the addition of a new glucose-lowering medication while glargine intensification was indicated by the addition of a new glucose-lowering medication or by a dose increase of at least 100%. The definition for intensification was modified for glargine as glargine dose is escalated upwards before adding any new medication. Dose was calculated for each glargine prescription by dividing the total insulin units dispensed for a prescription by the number of elapsed days between that dispense date and the next, as the actual dose of insulin prescribed is not recorded in the claims database.

**Treatment durability** was functionally defined as the absence of treatment modification and is measured as the time on index treatment without treatment modification (such as switching, intensifying, or discontinuing).

Analysis
--------

### Propensity score matching process

Because this was an observational study and randomization of patients is not possible, propensity score matching was used to ensure a similar distribution of specific characteristics between the exenatide and glargine patients. Propensity score matching reduces selection bias that might arise when comparing two different treatment options. Variables used in the 1:1 matching included the baseline characteristics listed in Table [1](#T1){ref-type="table"}: gender, age, geographic region, health plan type, CCI score, diabetes related complications, other common comorbidities, physician specialty, use of glucose lowering medications (not including blood glucose self-monitoring devices) and cardiovascular medications and healthcare resource use in the pre-index period.

###### 

Baseline demographic and clinical characteristics of patients before and after matching

  **Characteristic**                      **Pre-match**   **P value**   **Post-match**^**1**^                                                                     
  -------------------------------------- --------------- ------------- ----------------------- ---------- ----------- ---------- ---------- ---------- ---------- -----
  **Age: mean (years)**                        54             10                 59                12      \< 0.0001      57         10         57         12      7.8
  **Age: group**                                                                                           \< 0.0001                                                 
    18-34                                      267           2.9%                72               1.6%                    71        1.9%        66        1.7%     1.0
    35-44                                     1,183          12.9%               397              8.8%                   368        9.8%       381       10.1%     1.2
    45-54                                     3,135          34.1%              1,146            25.5%                  1,077      28.5%      1,073      28.4%     0.2
    55-64                                     3,307          36.0%              1,382            30.7%                  1,289      34.2%      1,272      33.7%     1.0
    65+                                       1,305          14.2%              1,502            33.4%                   969       25.7%       982       26.0%     0.8
  **Sex: female**                             5,359          58.3%              1,948            43.3%     \< 0.0001    1,720      45.6%      1,726      45.7%     0.3
  **Diabetes complications**                                                                                                                                      
   Microvascular                              1,521          16.5%              1,109            24.6%     \< 0.0001     769       20.4%       766       20.3%     0.2
   Macrovascular                              1,530          16.6%              1,349            30.0%     \< 0.0001     879       23.3%       906       24.0%     1.7
  **Deyo charlson Comorbidity index**          1.4            1.1                1.8              1.5      \< 0.0001     1.6        1.3        1.6        1.3      0.1
  **Medication claims**                       41.2           25.1               40.8              27.2       0.37        41.0       24.9       40.4       26.9     2.2
  **Medication classes**                       9.9            4.4                9.9              4.7        0.60        9.7        4.2        9.8        4.6      1.5
  **Pre-index inpatient admissions**           815           8.9%                952             21.2%     \< 0.0001     530       14.0%       543       14.4%     1.0
  **Pre-index total healthcare costs**       \$9,749       \$12,251           \$14,536          \$31,763   \< 0.0001   \$11,194   \$15,747   \$11,245   \$18,254   0.3
  **Physician specialty**                                                                                  \< 0.0001                                                 
   Primary care                               6,346          69.0%              3,170            70.5%                  2,722      72.1%      2,699      71.5%     1.4
   Endocrinology                              1,168          12.7%               210              4.7%                   204        5.4%       198        5.2%     0.7
   Other specialist                           1,016          11.0%               680             15.1%                   524       13.9%       529       14.0%     0.4
   Missing/unknown                             667           7.3%                439              9.8%                   324        8.6%       348        9.2%     2.2
  **Treatment pre-Index**                                                                                                                                         
   Glucose lowering                           9,188          99.9%              4,402            97.8%     \< 0.0001    3,765      99.8%      3,766      99.8%     0.6
   Biguanides (metformin)                     6,761          73.5%              2,940            65.3%     \< 0.0001    2,624      69.5%      2,626      69.6%     0.1
   Sulfonylureas                              4,252          46.2%              3,011            66.9%     \< 0.0001    2,445      64.8%      2,428      64.3%     0.9
   Meglitinides                                466           5.1%                259              5.8%       0.090       212        5.6%       216        5.7%     0.5
   Thiazolidinediones                         4,688          51.0%              2,382            52.9%       0.030      2,085      55.2%      2,082      55.2%     0.2
   α glucosidase inhibitors                    92            1.0%                69               1.5%      0.0065        44        1.2%        53        1.4%     2.1
   Fixed dose therapies                       2,293          24.9%               916             20.4%     \< 0.0001     854       22.6%       840       22.3%     0.9
   Cardiovascular                             8,493          92.3%              4,111            91.4%       0.049      3,470      91.9%      3,463      91.8%     0.7
   Antihyperlipidemics                        6,526          71.0%              3,074            68.3%      0.0016      2,648      70.2%      2,638      69.9%     0.6
   Antihypertensives                          7,693          83.6%              3,814            84.8%       0.091      3,183      84.3%      3,187      84.4%     0.3
   Other                                      3,164          34.4%              1,308            29.1%     \< 0.0001    1,089      28.9%      1,106      29.3%     1.0
   Antidepressants                            2,890          31.4%              1,138            25.3%     \< 0.0001     952       25.2%       978       25.9%     1.6
   Antiobesity                                 82            0.9%                10               0.2%     \< 0.0001      9         0.2%        10        0.3%     0.5
   Antiemetics/antinausea                      429           4.7%                260              5.8%      0.0051       202        5.4%       203        5.4%     0.1

^1^ Post-match balance was assessed by evaluating the standardized difference (std. diff.). All standardized differences were less than 2.5, except for mean age, which was 7.8.

Categorical variables were summarized by frequency and percentages. Continuous variables were reported by mean and standard deviation. Differences between treatments were tested for statistical significance using chi-square tests for categorical variables and t-tests or Wilcoxon rank tests for continuous variables. Kaplan-Meier plots were constructed to illustrate the probability of treatment modification for overall as well as each of the three modification measures in the post index period. Log-rank statistics and survival analysis were performed to assess the significance of the difference between treatments.

The data used for this study was based on an existing administrative health insurance claims database. There was no interaction with any subjects and the database does not include any individually identifiable data (e.g. does not include names, addresses, social security or medical record numbers, or any other obvious identifiers). The data is not developed or reported in a way that subjects can be identified, directly or through identifiers linked to subjects. According to information provided by the Office for Human Research Protections, this type of data is exempt for an IRB review under the requirements of the US Department of Health and Human Services regulations 45 CFR part 46. We acknowledge that many academic and medical institutions may have local IRBs that mandate that retrospective database studies apply for an IRB exemption; in this case there was no such mandate.

Results
=======

Demographic and clinical characteristics
----------------------------------------

A total of 9,197 exenatide and 4,499 glargine patients met all inclusion and exclusion criteria in the pre-index period, prior to propensity score matching (Table [1](#T1){ref-type="table"}). Propensity score matching resulted in a total of 3,774 matched pairs in the pre-index period. Baseline patient characteristics, including age, gender, health plan, clinical and resource use variables were balanced between the 2 cohorts after matching, with post-match standardized differences of less than 2.5 for all measures except age. Mean age in the exenatide cohort was 57.0 (standard deviation (SD = 10.8) years, compared to 57.8 (SD = 12.0) years in the glargine cohort (standardized difference = 7.8). Pre- and post-match descriptive measures are reported in Table [1](#T1){ref-type="table"}.

Treatment modification
----------------------

Compared to exenatide-treated patients, glargine-treated patients had lower treatment durability, demonstrated by higher rates of treatment modification and shorter time to treatment modification. Glargine-treated patients were 33% more likely to modify treatment \[hazard ratio (HR) = 1.33, p \< 0.0001\]. Compared to exenatide-treated patients, a significantly higher percentage of glargine-treated patients experienced treatment modification in the 18 months post-index period (Table [2](#T2){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). By 18 months, treatment modification was observed in 76.0% of the glargine cohort vs. 69.1% of the exenatide cohort (p \< 0.0001). Patients initiating exenatide, were on their treatment longer before any modification compared to glargine-treated patients (159 vs. 123 days, p \< 0.0001) indicating longer treatment durability.

###### 

Treatment modification: frequency and timing

  **Modification**                                                                           **Patients treated with**   **P value**                  
  ----------------------------------------------------------------------------------------- --------------------------- ------------- ------- ------- -----------
  **Any type of treatment modification (Discontinuation, switching, or intensification)**                                                             
   By day 180 of follow-up                                                                             1,629                44.7%      2,169   59.6%   \< 0.0001
   By day 365 of follow-up                                                                             2,284                62.7%      2,616   71.8%   \< 0.0001
   By day 545 of follow-up                                                                             2,515                69.1%      2,768   76.0%   \< 0.0001
   Mean days to modification†                                                                           159                  123        123     112    \< 0.0001
  **Intensification**                                                                                                                                 
   By day 180 of follow-up                                                                              394                 10.8%       660    18.1%   \< 0.0001
   By day 365 of follow-up                                                                              538                 14.8%       856    23.5%   \< 0.0001
   By day 545 of follow-up                                                                              580                 15.9%       947    26.0%   \< 0.0001
   Mean days to intensification†                                                                        150                  117        154     128      0.541
  **Discontinuation**                                                                                                                                 
   By day 180 of follow-up                                                                              902                 24.8%      1,163   31.9%   \< 0.0001
   By day 365 of follow-up                                                                             1,264                34.7%      1,396   38.3%    0.0013
   By day 545 of follow-up                                                                             1,394                38.3%      1,456   40.0%     0.14
   Mean days to discontinuation†                                                                        156                  124        111     105    \< 0.0001
  **Switching**                                                                                                                                       
   By day 180 of follow-up                                                                              333                 9.1%        304    8.3%      0.23
   By day 365 of follow-up                                                                              482                 13.2%       340    9.3%    \< 0.0001
   By day 545 of follow-up                                                                              541                 14.9%       365    10.0%   \< 0.0001
   Mean days to switching†                                                                              177                  125        125     112    \< 0.0001

\* Patients with incomplete or invalid data on pharmacy claims were dropped; matched controls for these patients were also dropped.

† Mean days were calculated among patients with the specified modification.
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Glargine-treated patients were 72% more likely to intensify therapy (HR = 1.72, p \< 0.0001), with 26% of the glargine cohort vs. 15.9% of the exenatide cohort (p \< 0.0001) having intensified by 18 months. The average time until treatment intensification was similar between exenatide and glargine patients (150 days vs. 154 days, p = 0.541). Similarly, there was a 25% greater likelihood of discontinuation of therapy in the glargine vs. exenatide cohorts (HR = 1.25, p \< 0.0001). The average time until discontinuation was 156 days for exenatide-treated patients and 111 days for glargine-treated patients (p \< 0.0001). Switching was the only treatment modification less likely to occur with glargine relative to exenatide-treated patients (HR = 0.71, p \< 0.0001). However, among patients who did switch therapies, the average time until switching treatments was longer for exenatide-treated patients (177 days) compared to insulin glargine-treated patients (125 days, p \< 0.0001).

Within the exenatide cohort, the most commonly used drug for intensification was biguanides (34.3% of patients with intensification), followed by sulfonylureas (18.3%) (Table [3](#T3){ref-type="table"}). Glargine was used in only 8.3% of patients who initiated exenatide. Within the glargine cohort, intensification was most often accomplished by increasing the glargine dose (28.0%), followed by use of non-glargine insulin (21.1%). Intensification with exenatide was observed in only 5.9% of patients who initiated with glargine. Exenatide-treated patients who switched most often switched to sitagliptin (27.0%) or glargine (20.9%), whereas glargine-treated patients switched to a non-glargine insulin (27.1%), sulfonylureas (13.7%), biguanides (13.4%), or exenatide (13.2%).

###### 

Treatment modification: specific drugs used in switching and intensification

  **Drug**                             **Patients treated with**                
  ----------------------------------- --------------------------- ------- ----- -------
  **Modification: Intensification**               580              100%    947   100%
   Exenatide BID                                   0               0.0%    56    5.9%
   Insulin glargine                               48               8.3%    265   28.0%
  Dose increased at least 100%                                             92    9.7%
   Other insulin                                  28               4.8%    200   21.1%
   Pre-mixed                                       2               0.3%    13    1.4%
   Bolus                                           3               0.5%    184   19.4%
   Basal (other than glargine)                    23               4.0%     3    0.3%
  Oral                                                                          
   Sitagliptin                                    41               7.1%    65    6.9%
   α glucosidase inhibitors                        1               0.2%     1    0.1%
   Thiazolidinediones                             67               11.6%   85    9.0%
   Meglitinides                                   14               2.4%    24    2.5%
   Sulfonylureas                                  106              18.3%   78    8.2%
   Biguanides                                     199              34.3%   114   12.0%
   Fixed dose therapies                           76               13.1%   54    5.7%
  Other injectable/pramlintide                     0               0.0%     5    0.5%
  **Modification: switching**                     541              100%    365   100%
   Exenatide BID                                   0               0.0%    48    13.2%
   Insulin glargine                               113              20.9%    0    0.0%
   Other insulin                                  65               12.0%   99    27.1%
    Pre-mixed                                     17               3.1%    55    15.1%
    Bolus                                         15               2.8%    23    6.3%
    Basal (other than glargine)                   33               6.1%    21    5.8%
  Oral                                                                          
   Sitagliptin                                    146              27.0%   31    8.5%
   α glucosidase inhibitors                        2               0.4%     0    0.0%
   Thiazolidinediones                             39               7.2%    46    12.6%
   Meglitinides                                    8               1.5%     9    2.5%
   Sulfonylureas                                  45               8.3%    50    13.7%
   Biguanides                                     69               12.8%   49    13.4%
   Fixed dose therapies                           52               9.6%    33    9.0%
  Other injectable/Pramlintide                     2               0.4%     0    0.0%

\* Patients with incomplete or invalid data on pharmacy claims were dropped; matched controls for these patients were also dropped.

† Percentages were calculated among patients with the specified modification.

Discussion
==========

There is little information on the 'real-world' medication utilization patterns for patients with type 2 diabetes initiating exenatide BID or glargine. The strength of this study is that it provides the 'real-world' data on physician prescribing behavior and patient medication use behavior over 18 months follow-up period in usual care settings. These observations used robust statistical approaches including propensity analyses to insure that the groups being compared were similar at baseline. In the current retrospective observational study, exenatide-treated patients had greater treatment durability as measured by a lower probability of treatment modification and a longer time to treatment modification. Glargine-treated patients were 33% more likely to modify (discontinue, intensify or switch) their treatment compared to exenatide-treated patients over the 18-month post-index period showing a consistent and steady difference, favorable to exenatide. The findings of this study are significant given the ongoing challenges associated with managing patients on therapies such as insulin or exenatide for achieving and maintaining glycemic control \[[@B10],[@B11]\].

Treatment management for diabetes is often suboptimal, characterized by high rates of discontinuation, non-adherence, and lack of treatment modification \[[@B12]\], all of which are potential indicators of inadequate disease management including suboptimal glycemic control. Lower rates of persistence with insulin among new users are well-established; for example Cooke et al. reported that only 28.7% of new insulin users were persistent at 12 months \[[@B10]\]. In addition, a review article by Stephens et al. reported that better treatment persistence was associated with lower rates of diabetes-related complications, and also with reduced healthcare costs \[[@B13]\].

In the current study, exenatide-treated patients were less likely to discontinue or intensify treatment compared to glargine-treated patients. This is consistent with previously published reports by Fabunmi et al. \[[@B11]\] and Segal et al. \[[@B14]\]. Fabunmi et al. found that, compared to patients treated with glargine, exenatide-treated patients had a higher medication adherence (68.4% vs. 57.9%, p \< 0.001), were more likely to have an adherence of at least 80% (46.9% vs. 29.4%, p \< 0.001), and less likely to have either a 60 or 90-day gap in therapy (p \< 0.001).

This current study did not examine reasons for treatment modification and there are multiple hypotheses as to why responses to or treatment patterns with these therapies might differ. For example, weight gain and hypoglycemia have been reported as significant reasons for discontinuation/switching of insulin therapy among patients with type 2 diabetes \[[@B15]\]. By contrast, exenatide has been shown to reduce patient weight \[[@B16]-[@B18]\], without increasing the risk of hypoglycemia common to several other glucose-lowering therapies \[[@B19]\]. In addition, the higher discontinuation rate without switching to another medication in glargine-treated patients could be due to tolerance issues or poor compliance; alternatively, this could be due to improved pancreatic beta cell function. Other potential reasons for treatment modification could be due to factors unrelated to improved glycemic control, such as cost or convenience. In addition, exenatide is a fixed dose therapy while glargine requires dose adjustment. Most patients who initiate glargine with low dose of 10 units per day would require an increase in dose to reach to the average dose of 30-40 units per day; this could be another reason that may influence treatment modification. In order to reduce this bias, the dose increase of 100% or more is considered as treatment modification for glargine patients. This study also found that glargine-treated patients were less likely to switch treatments than exenatide-treated patients (HR:0.71, p \< 0.0001), which could be due, in part, to poorer tolerability of exenatide compared to insulin glargine. However, the exact reasons for treatment modifications cannot be identified with certainty from the current study and claims database.

Like any retrospective database analyses, this study has some limitations. First, the database comprised patients with commercial insurance coverage and results may not be generalizable to other patient populations. Second, clinical measures of glycemic control such as HbA1c or hypoglycemia and disease duration or severity are not available in this dataset. In the absence of HbA1c, diabetes-related complications, comorbidities and medication use in the pre-index period were used as a proxy to control for severity of disease in propensity score matching. Other variables impacting diabetes control, such as duration of diabetes, body weight/body mass index and adherence with life style modifications were not available in the database. Third, treatment modification measures were based on the presence or absence of prescription claims. These measures do not provide record of when or if medications were actually used; as such, this is an analysis of prescription filling patterns and not necessarily patient medication utilization behavior. Similarly, actual dose of insulin prescribed was not recorded in the claims database. Insulin glargine dose was calculated based upon insulin units dispensed and prescription refill dates, potentially leading to an overestimation of the quantity of insulin used by patients. Treatment intensification due to increased glargine dose, therefore, was defined as a 100% dose increase from one claim to the next in order to compensate for a potential overestimation of daily insulin doses. This approach was chosen to help insure that insulin glargine-treated patients who refilled their prescriptions early were not misclassified as patients intensifying treatment. This is the most conservative way of defining dose escalation for glargine in order to reduce potential bias towards exenatide. Fourth, while propensity score matching was used to reduce potential selection bias, and create two comparable patient groups, it does not control for potential unmeasured confounding variables. Also, the study only followed patients for 18 months following treatment initiation so adverse events (and related treatment modification) occurring after 18 months are not captured in this current analysis; it is unclear if longer term tolerability issues would have a differential impact on insulin glargine and exenatide. Limited information is available about the healthcare professionals that patients interact with, including prescribing physician speciality, educational programs, or medication therapy management initiatives often conducted by pharmacists or diabetes educators. This current analysis could not assess the presence of these resources or if access to them was different by study cohort. Lastly, it is important to note that the observational nature of the study design does not permit causal inferences.

Conclusions
===========

In conclusion, this study provides 'real-world' data showing significant differences in treatment modification rates for exenatide BID and insulin glargine, indicating potential for longer treatment durability for patients initiating exenatide BID. Future research should also examine the basis for the better medication utilization patterns associated with exenatide BID and whether those patterns translate into better clinical and economic outcomes.
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